Merck & Co., Inc. (MRK) Tops Q4 EPS by 2c; Guides In-Line
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $135.55 +1.98%
Financial Fact:
Less: Net Income Attributable to Noncontrolling Interests: 122.8M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Less: Net Income Attributable to Noncontrolling Interests: 122.8M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Merck & Co., Inc. (NYSE: MRK) reported Q4 EPS of $0.83, $0.02 better than the analyst estimate of $0.81. Revenue for the quarter came in at $11.7 billion versus the consensus estimate of $11.46 billion.
Merck & Co., Inc. sees FY2013 EPS of $3.60-3.70, versus the consensus of $3.69.
For earnings history and earnings-related data on Merck & Co., Inc. (MRK) click here.
Merck & Co., Inc. sees FY2013 EPS of $3.60-3.70, versus the consensus of $3.69.
For earnings history and earnings-related data on Merck & Co., Inc. (MRK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
- Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
